Ablynx is preparing to a US filing for its caplacizumab for the rare, life-threatening blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) following additional data from a ...

Sanofi is to pay Ablynx up to €2.4 billion to develop drugs for immune-related inflammatory diseases based on the biotech’s nanobody technology. The Paris-headquartered pharma firm is ...